$SAGE The MOUNTAIN study results have been reflected by the stock movement, Raymond James analyst Dane Leone said. The analyst expects ongoing clinical development of SAGE-217 to generate substantial debate within the investor and clinical community. As such, the analyst awaits a clearer outline of clinical catalysts for 2020.